Antiglutamate Anticonvulsants in the Treatment of Alcohol Withdrawal Syndrome
Information source: St. Petersburg State Pavlov Medical University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Topiramate; Lamotrigine; Memnatine; Diazepam; Placebo
Intervention: Anticonvulsants (Drug)
Phase: N/A
Status: Completed
Sponsored by: St. Petersburg State Pavlov Medical University Official(s) and/or principal investigator(s): Evgeny M Krupitsky, MD, PhD, Principal Investigator, Affiliation: St. Petersburg State Pavlov Medical University
Summary
The study is aimed to evaluate the efficacy of antiglutamate anticonvulsants (topiramate,
lamotrigine, and memantine) in the treatment of alcohol withdrawal syndrome
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
Eligibility
Minimum age: 20 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Alcohol dependence Alcohol withdrawal syndrome
Exclusion Criteria:
Drug dependence Major psychiatric diagnoses Severe somatic illness
Locations and Contacts
Additional Information
Last updated: October 17, 2006
|